New fibrinolytic agents for MI: as effective as current agents, but easier to administer.
Review
Overview
abstract
The efficacy and safety of fibrinolytic agents have not dramatically changed since alteplase (Activase), a derivative of tissue plasminogen activator (t-PA), was introduced nearly 2 decades ago. However, newer agents have a longer half-life, making them easier to deliver. Fibrinolytic therapy is underused in many patients, especially in those traditionally thought to be at high risk for complications.
